B M Jonkman-Berk1, J M van den Berg2, I J M Ten Berge3, R G M Bredius4, G J Driessen5, V A S H Dalm6, J T van Dissel7, M van Deuren8, P M Ellerbroek9, M van der Flier10, P M van Hagen11, J M van Montfrans12, A Rutgers13, E H Schölvinck14, E de Vries15, R T van Beem16, T W Kuijpers17. 1. Emma Children's Hospital, Academic Medical Center (AMC), Dept. of Pediatric Hematology, Immunology and Infectious Diseases, University of Amsterdam (UvA), Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. Electronic address: bmjonkman@gmail.com. 2. Emma Children's Hospital, Academic Medical Center (AMC), Dept. of Pediatric Hematology, Immunology and Infectious Diseases, University of Amsterdam (UvA), Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. Electronic address: j.m.vandenberg@amc.uva.nl. 3. Academic Medical Center (AMC), Dept. of Internal Medicine, UvA, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. Electronic address: r.j.tenberge@amc.uva.nl. 4. Leiden University Medical Center (LUMC), Dept. of Pediatrics, PO box 9600, 2300 RC Leiden, The Netherlands. Electronic address: R.G.M.Bredius@lumc.nl. 5. Erasmus Medical Center (ErasmusMC), Sophia Children's Hospital, Dept. of Pediatric Infectious Diseases and Immunology, PO box 2030, 3000 CB Rotterdam, The Netherlands. Electronic address: g.driessen@erasmusmc.nl. 6. EMC, Dept. of Clinical Immunology, PO box 2040, 3000 CA Rotterdam, The Netherlands. Electronic address: v.dalm@erasmusmc.nl. 7. LUMC, Dept. of Infectious Diseases, PO box 9600, 2300 RC Leiden, The Netherlands. Electronic address: J.T.van_Dissel@lumc.nl. 8. Radboud University Medical Center, Dept. of Internal Medicine, PO box 9101, 6500 HB Nijmegen, The Netherlands; Radboudumc Institute of Molecular Life Sciences (RIMLS), PO box 9101, 6500 HB Nijmegen, The Netherlands. Electronic address: Marcel.vanDeuren@radboudumc.nl. 9. University Medical Center Utrecht, Dept. of Infectious Diseases, PO box 85500, 3509 GA Utrecht, The Netherlands. Electronic address: P.Ellerbroek@umcutrecht.nl. 10. Radboud University Medical Center, Dept. of Pediatric Infectious Diseases and Immunology, PO Box 9101, 6500 HB Nijmegen, The Netherlands; Radboudumc Institute of Molecular Life Sciences (RIMLS), PO box 9101, 6500 HB Nijmegen, The Netherlands. Electronic address: Michiel.vanderFlier@radboudumc.nl. 11. EMC, Dept. of Clinical Immunology, PO box 2040, 3000 CA Rotterdam, The Netherlands. Electronic address: p.m.vanhagen@erasmusmc.nl. 12. University Medical Center Utrecht, Wilhelmina Children's Hospital, Dept. of Pediatric Immunology and Infectious Diseases, PO box 85090, 3508 AB Utrecht, The Netherlands. Electronic address: J.vanMontfrans@umcutrecht.nl. 13. University Medical Center Groningen (UMCG), Dept. of Rheumatology and Clinical Immunology, PO box 30.001, 9700 RB Groningen, The Netherlands. Electronic address: a.rutgers@umcg.nl. 14. University Medical Center Groningen/Beatrix Children's Hospital, Dept. of Pediatric Immunology and Infectious Diseases, PO box 30.001, 9700 RB Groningen, The Netherlands. Electronic address: e.h.scholvinck@umcg.nl. 15. Jeroen Bosch Hospital, Dept. of Pediatrics, PO box 90153, 5200 ME 's-Hertogenbosch, The Netherlands. Electronic address: E.d.Vries@jbz.nl. 16. Sanquin Blood Supply Foundation, Medical Department, PO box 9190, 1006 AD Amsterdam, The Netherlands. Electronic address: R.vanbeem@sanquin.nl. 17. Emma Children's Hospital, Academic Medical Center (AMC), Dept. of Pediatric Hematology, Immunology and Infectious Diseases, University of Amsterdam (UvA), Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. Electronic address: t.w.kuijpers@amc.nl.
Abstract
PURPOSE: To analyze the data of the national registry of all Dutch primary immune deficiency (PID) patients, according to the European Society for Immunodeficiencies (ESID) definitions. RESULTS: In the Netherlands, 745 patients had been registered between 2009 and 2012. An overall prevalence of 4.0 per 100,000 inhabitants was calculated. The most prevalent PID was 'predominantly antibody disorder (PAD)' (60.4%). In total, 118 transplantations were reported, mostly hematopoietic stem cell transplantations (HSCT). Almost 10% of the PID patients suffered from a malignancy, in particular 'lymphoma' and 'skin cancer'. Compared to the general Dutch population, the relative risk of developing any malignancy was 2.3-fold increased, with a >10-fold increase for some solid tumors (thymus, endocrine organs) and hematological disease (lymphoma, leukemia), varying per disease category. CONCLUSIONS: The incidence rate and characteristics of PID in the Netherlands are similar to those in other European countries. Compared to the general population, PID patients carry an increased risk to develop a malignancy.
PURPOSE: To analyze the data of the national registry of all Dutch primary immune deficiency (PID) patients, according to the European Society for Immunodeficiencies (ESID) definitions. RESULTS: In the Netherlands, 745 patients had been registered between 2009 and 2012. An overall prevalence of 4.0 per 100,000 inhabitants was calculated. The most prevalent PID was 'predominantly antibody disorder (PAD)' (60.4%). In total, 118 transplantations were reported, mostly hematopoietic stem cell transplantations (HSCT). Almost 10% of the PID patients suffered from a malignancy, in particular 'lymphoma' and 'skin cancer'. Compared to the general Dutch population, the relative risk of developing any malignancy was 2.3-fold increased, with a >10-fold increase for some solid tumors (thymus, endocrine organs) and hematological disease (lymphoma, leukemia), varying per disease category. CONCLUSIONS: The incidence rate and characteristics of PID in the Netherlands are similar to those in other European countries. Compared to the general population, PID patients carry an increased risk to develop a malignancy.
Authors: Samuele Renzi; Karin Petra Sabine Langenberg-Ververgaert; Nicolas Waespe; Salah Ali; Jack Bartram; Orli Michaeli; Julia Upton; Michaela Cada Journal: Eur J Pediatr Date: 2020-03-11 Impact factor: 3.183
Authors: Paul C Mayor; Kevin H Eng; Kelly L Singel; Scott I Abrams; Kunle Odunsi; Kirsten B Moysich; Ramsay Fuleihan; Elizabeth Garabedian; Patricia Lugar; Hans D Ochs; Francisco A Bonilla; Rebecca H Buckley; Kathleen E Sullivan; Zuhair K Ballas; Charlotte Cunningham-Rundles; Brahm H Segal Journal: J Allergy Clin Immunol Date: 2017-06-09 Impact factor: 10.793
Authors: Michael F Walsh; Vivian Y Chang; Wendy K Kohlmann; Hamish S Scott; Christopher Cunniff; Franck Bourdeaut; Jan J Molenaar; Christopher C Porter; John T Sandlund; Sharon E Plon; Lisa L Wang; Sharon A Savage Journal: Clin Cancer Res Date: 2017-06-01 Impact factor: 12.531
Authors: Andishe Attarbaschi; Elisa Carraro; Oussama Abla; Shlomit Barzilai-Birenboim; Simon Bomken; Laurence Brugieres; Eva Bubanska; Birgit Burkhardt; Alan K S Chiang; Monika Csoka; Alina Fedorova; Janez Jazbec; Edita Kabickova; Zdenka Krenova; Jelena Lazic; Jan Loeffen; Georg Mann; Felix Niggli; Natalia Miakova; Tomoo Osumi; Leila Ronceray; Anne Uyttebroeck; Denise Williams; Wilhelm Woessmann; Grazyna Wrobel; Marta Pillon Journal: Haematologica Date: 2016-08-11 Impact factor: 9.941